These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
464 related items for PubMed ID: 28271623
1. A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS. Hod K, Sperber AD, Ron Y, Boaz M, Dickman R, Berliner S, Halpern Z, Maharshak N, Dekel R. Neurogastroenterol Motil; 2017 Jul; 29(7):. PubMed ID: 28271623 [Abstract] [Full Text] [Related]
2. The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea-predominant irritable bowel syndrome. Hod K, Dekel R, Aviv Cohen N, Sperber A, Ron Y, Boaz M, Berliner S, Maharshak N. Neurogastroenterol Motil; 2018 Dec; 30(12):e13456. PubMed ID: 30136337 [Abstract] [Full Text] [Related]
3. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG. J Clin Gastroenterol; 2012 Mar; 46(3):220-7. PubMed ID: 22157240 [Abstract] [Full Text] [Related]
4. Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms: A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial. Francavilla R, Piccolo M, Francavilla A, Polimeno L, Semeraro F, Cristofori F, Castellaneta S, Barone M, Indrio F, Gobbetti M, De Angelis M. J Clin Gastroenterol; 2019 Mar; 53(3):e117-e125. PubMed ID: 29688915 [Abstract] [Full Text] [Related]
5. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome. Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP. BMC Gastroenterol; 2018 May 25; 18(1):71. PubMed ID: 29801486 [Abstract] [Full Text] [Related]
6. Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. Pinto-Sanchez MI, Hall GB, Ghajar K, Nardelli A, Bolino C, Lau JT, Martin FP, Cominetti O, Welsh C, Rieder A, Traynor J, Gregory C, De Palma G, Pigrau M, Ford AC, Macri J, Berger B, Bergonzelli G, Surette MG, Collins SM, Moayyedi P, Bercik P. Gastroenterology; 2017 Aug 25; 153(2):448-459.e8. PubMed ID: 28483500 [Abstract] [Full Text] [Related]
7. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, Yoon BC, Choi HS, Chung WS, Seo JG. J Gastroenterol Hepatol; 2014 Jan 25; 29(1):52-9. PubMed ID: 23829297 [Abstract] [Full Text] [Related]
8. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. Choi CH, Kwon JG, Kim SK, Myung SJ, Park KS, Sohn CI, Rhee PL, Lee KJ, Lee OY, Jung HK, Jee SR, Jeen YT, Choi MG, Choi SC, Huh KC, Park H. Neurogastroenterol Motil; 2015 May 25; 27(5):705-16. PubMed ID: 25809913 [Abstract] [Full Text] [Related]
9. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P. Gastroenterol Clin Biol; 2008 Feb 25; 32(2):147-52. PubMed ID: 18387426 [Abstract] [Full Text] [Related]
10. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Sun YY, Li M, Li YY, Li LX, Zhai WZ, Wang P, Yang XX, Gu X, Song LJ, Li Z, Zuo XL, Li YQ. Sci Rep; 2018 Feb 14; 8(1):2964. PubMed ID: 29445178 [Abstract] [Full Text] [Related]
11. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. J Clin Gastroenterol; 2011 Sep 14; 45(8):679-83. PubMed ID: 21301358 [Abstract] [Full Text] [Related]
12. Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial. Han K, Wang J, Seo JG, Kim H. J Gastroenterol; 2017 Apr 14; 52(4):432-443. PubMed ID: 27178566 [Abstract] [Full Text] [Related]
13. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. Gastroenterology; 2014 Jan 14; 146(1):67-75.e5. PubMed ID: 24076059 [Abstract] [Full Text] [Related]
14. The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study. Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, Majsiak E, Bierła JB, Kanarek E, Sowińska A, Cukrowska B. Nutrients; 2021 Feb 26; 13(3):. PubMed ID: 33652763 [Abstract] [Full Text] [Related]
15. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome. Srivastava S, Basak U, Naghibi M, Vijayakumar V, Parihar R, Patel J, Jadon PS, Pandit A, Dargad RR, Khanna S, Kumar S, Day R. Gut Microbes; 2024 Feb 26; 16(1):2338322. PubMed ID: 38630015 [Abstract] [Full Text] [Related]